// App-Quantinova.ai

: First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.

Researchers

Presenter

  • Rahul Raj Aggarwal

Principal Investigators

  • Jingsong Zhang

  • Xinhua Zhu

  • Paul Monk

  • Robert J. Jones

  • Mark David Linch

  • Dan Costin

  • Johann S. De Bono

  • Lawrence Ivan Karsh

  • Daniel P. Petrylak

  • Pascal Borderies

  • Rashmi Majali Deshpande

  • Amir Hafeez

  • Vincent J. O'Neill

  • Scott T. Tagawa

Medical Centers

  • Institute of Cancer Science, University of Glasgow, Glasgow, United Kingdom

  • The Urology Center of Colorado, Denver, CO

  • Yale Cancer Center, Yale School of Medicine, New Haven, CT

  • Weill Cornell Medicine, Division of Hematology & Medical Oncology, NewYork-Presbyterian Hospital, New York, NY

  • Northwell Health System, New Hyde Park, NY

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Richard J. Solove Research Institute, Columbus, OH

  • Moffitt Cancer Center, Tampa, FL

  • Center for Cancer Care at White Plains Hospital, White Plains, NY

  • Bioxcel Therapeutics, New Haven, CT

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Bioxcel Therapeutics, New Haven, CT

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Simon'S Two Stage Design

Phase

  • II

Study Id's

  • NCT03910660

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved